Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 28 · below the Ichimoku cloud · RSI 17 (oversold) · MACD above its signal · 1% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.1M | 0.00% | 1.26M | −9.1% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NMRA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Aurora Daljit SinghChief Operating Officer | Conversion of Exercise of derivative security at price 0.72 per share. | 176.1K | $126.76K |
| Aug 20, 2026 | Aurora Daljit SinghChief Operating Officer | Sale at price 1.51 - 1.60 per share. | 176.1K | $269.97K |
| Aug 18, 2026 | Aurora Daljit SinghOfficer | Conversion of Exercise of derivative security at price 0.72 per share. | 243.8K | $175.50K |
| Aug 18, 2026 | Aurora Daljit SinghOfficer | Sale at price 1.49 - 1.65 per share. | 277.8K | $431.67K |
| Feb 16, 2026 | Berns Paul LChief Executive Officer | Sale at price 3.51 per share. | 9.8K | $34.46K |
| Feb 16, 2026 | Aurora Daljit SinghChief Operating Officer | Sale at price 3.56 per share. | 6.2K | $21.92K |
| Feb 16, 2026 | Pinto Joshua Ph.D.President | Sale at price 3.54 per share. | 6K | $21.09K |
| Feb 16, 2026 | Milligan Michael LeeChief Financial Officer | Sale at price 3.56 per share. | 1.4K | $5.12K |
| Nov 10, 2025 | Aurora Daljit SinghChief Operating Officer | Sale at price 2.68 per share. | 114.7K | $307.03K |
| Oct 26, 2025 | Burow Kristina MDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.61 per share. | 1.92M | $5.00M |
| Oct 26, 2025 | Arch Venture Partners Xii, LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 2.61 per share. | 1.92M | $5.00M |
| May 20, 2025 | Pinto Joshua Ph.D.President | Stock Gift at price 0.00 per share. | 13.2K | — |
| Feb 17, 2025 | Berns Paul LChief Executive Officer | Sale at price 1.69 per share. | 13.9K | $23.47K |
| Feb 17, 2025 | Aurora Daljit SinghOfficer | Sale at price 1.68 per share. | 8.6K | $14.35K |
| Feb 17, 2025 | Lenz Robert AOfficer | Sale at price 1.67 per share. | 5.6K | $9.38K |
| Feb 17, 2025 | Pinto Joshua Ph.D.President | Sale at price 1.67 per share. | 8K | $13.48K |
| Feb 17, 2025 | Milligan Michael LeeOfficer | Sale at price 1.69 per share. | 2K | $3.35K |
| Dec 26, 2024 | Berns Paul LDirector | Stock Gift at price 0.00 per share. | 399.3K | — |
| Oct 17, 2024 | Fust Matthew K.Director | Conversion of Exercise of derivative security at price 2.52 - 8.79 per share. | 21.8K | $127.04K |
| Oct 17, 2024 | Fust Matthew K.Director | Sale at price 17.01 - 17.03 per share. | 21.8K | $370.96K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.2 | 75.4 | -44.1 | 26.7 | -25.1 | -8.1 | -5.3 | -17.4 | -55.2 | -40.5 | −80.2% | ||
| 2025 | -81.8 | -19.2 | -35.9 | -22.0 | -8.2 | 2.4 | 167.4 | -11.7 | 5.2 | 65.9 | -25.8 | -20.1 | −83.1% |
| 2024 | -12.6 | 18.3 | -22.0 | -33.9 | 8.9 | -0.7 | 30.8 | -10.6 | 14.9 | -13.3 | -13.2 | 6.6 | −37.8% |
| 2023 | -22.6 | 12.2 | 39.2 | +20.8% |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Buy / hold / sell counts